Precipio Valuation
Is TGK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TGK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TGK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TGK's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TGK?
Key metric: As TGK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is TGK's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | US$13.26m |
| Market Cap | US$9.24m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | -1.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does TGK's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
V3V VITA 34 | 0.9x | 3.1% | €72.5m |
UOM AS Latvijas Juras medicinas centrs | 0.5x | n/a | €5.4m |
EIF MedNation | 0.1x | n/a | €5.0m |
TLIK Arzneiwerk VIDA | 0.08x | n/a | €4.5m |
TGK Precipio | 0.7x | 55.8% | €9.2m |
Price-To-Sales vs Peers: TGK is expensive based on its Price-To-Sales Ratio (0.7x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does TGK's PS Ratio compare vs other companies in the DE Healthcare Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
TLIK Arzneiwerk VIDA | 0.08x | n/a | US$4.67m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: TGK is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Healthcare industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is TGK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | 2.5x |
Price-To-Sales vs Fair Ratio: TGK is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%